Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Case Report on Primary Cutaneous Adenoid Cystic Carcinoma of the Right Forearm and Its Dermoscopic Characteristics

  • By

  • Si Li

  • Xue Cheng

  • Ronggui Xing

  • Zhenyin Peng

  • Tianyou Xiong

  • Yanan Jiang

  • Xianbiao Zou

  • August 31, 2026

Share

Clinical Scorecard: Correction: Case Report on Primary Cutaneous Adenoid Cystic Carcinoma of the Right Forearm and Its Dermoscopic Characteristics

At a Glance

CategoryDetail
ConditionPrimary Cutaneous Adenoid Cystic Carcinoma
Key MechanismsNot specified
Target PopulationNot specified
Care SettingDermatology

Key Highlights

  • Correction of figure placements in the original article
  • Figures 1 and 2 were interchanged
  • Updated images and captions provided

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not specified

          Not specified

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

            • by Si Li, Xue Cheng, Ronggui Xing, Zhenyin Peng, Tianyou Xiong, Yanan Jiang, Xianbiao Zou

            • August 31, 2026

            Related Content

            Genetic Testing in Retinoblastoma: New Applications

            Liquid biopsy and molecular profiling are expanding the diagnostic and prognostic role of genetic testing in retinoblastoma.

            Coding for Ocular Tumors

            Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

            This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

            A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

            • August 31, 2026

            • 5 min